Esperion Therapeutics (ESPR) Income from Continuing Operations (2012 - 2026)

Esperion Therapeutics has reported Income from Continuing Operations for 15 years, with the latest figure at 26379000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 36.48% year-over-year to 26379000.0; the trailing twelve-month figure through Mar 2026 stood at 9183000.0 (up 91.86% YoY), and the FY2025 full-year result was 22682000.0, up 56.17% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 26379000.0, down from 62597000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 62597000.0 in Q4 2025, with the low at 66642000.0 in Q2 2022.
• Historically, Income from Continuing Operations has averaged 30273176.47 across 5 years, with a median of 41527000.0 in 2025.
• The largest YoY upside for Income from Continuing Operations was 315.28% in 2025 against a maximum downside of 171.3% in 2025.
• Esperion Therapeutics' Income from Continuing Operations stood at 56842000.0 in 2022, then fell by 1.02% to 57424000.0 in 2023, then jumped by 49.36% to 29077000.0 in 2024, then jumped by 315.28% to 62597000.0 in 2025, then plunged by 142.14% to 26379000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 26379000.0 (Q1 2026), 62597000.0 (Q4 2025), and 32010000.0 (Q3 2025), per Business Quant data.